H
Halozyme Therapeutics, Inc. (HALO)
NMS – Real vaqt narxi. Valyuta: USD
70.88
-0.05 (-0.07%)
Bozor ochiq: May 13, 2026, 9:38 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
70.88
-0.05 (-0.07%)
Bozor ochiq: May 13, 2026, 9:38 AM EDT
Halozyme Therapeutics, Inc., biopharmaceutical kompaniyasi, Qo'shma Shtatlar, Shveytsariya, Belgiya, Yaponiya va xalqaro miqyosda patentlangan fermentlar va qurilmalarni tadqiq qiladi, ishlab chiqadi va tijoratlashtiradi. Kompaniyaning mahsulotlari patentlangan rekombinant inson gialuronidaza fermenti (rHuPH20) ga asoslangan bo'lib, u monoklonal antitelalar va boshqa terapevtik molekulalar, shuningdek, kichik molekulalar va suyuqliklar kabi in'ektsion biologik vositalarni etkazib berish imkonini beradi. U Hylenex rekombinantini, rHuPH20 formulasi, u teri osti (SC) yuborilishini osonlashtiradi, SC urographyda boshqa in'ektsiya qilinadigan dorilarni tarqatish va singishini kuchaytirish va radiopak agentlarning so'rilishini oshirish uchun; va XYOSTED, testosteronni almashtirish terapiyasini SC yuborish uchun in'ektsiya taklif etadi. Kompaniya, shuningdek, Herceptin Hylecta brendi ostida Herceptin (trastuzumab) va ko'krak bezi saratonini davolash uchun Phesgo; surunkali limfotsitik leykemiyani davolash uchun Mabthera SC; IV infuziya uchun Tecentriq SC; ko'p skleroz uchun Ocrevus SC; birlamchi immun tanqisligi kasalliklarini davolash uchun HYQVIA; amiloidoz, va yashirin va ko'p miyelomani davolash uchun DARZALEX; allergik reaktsiyalarni davolash uchun epinefrin in'ektsiyasi; metastatik yoki rezektsiya qilinmaydigan melanomani davolash uchun nivolumab va relatlimab; teriparatid in'ektsiyalari; ARGX-113; va ko'p fokusli motor neyropatiyasida og'ir otoimmün kasalliklarni davolash uchun ARGX-117 taqdim etadi. U F. Hoffmann-La Roche, Ltd. va Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG va Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; va Skye Bioscience, Inc. bilan hamkorlik va litsenziyalash shartnomalariga ega. Kompaniya 1998 yilda tashkil etilgan va San-Diego, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Charles P. Theuer M.D., Ph.D. | Chief Medical Officer |
| Dr. Christopher Wahl M.B.A., M.D. | Chief Scientific Officer |
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, CEO & Director |
| Mr. Chase Coffman Ph.D. | President of Hypercon |
| Mr. David A. Ramsay MBA | Interim Chief Financial Officer |
| Mr. Mark Snyder Esq. | Senior VP, General Counsel, Chief Compliance Officer & nd Secretary |
| Mr. Paul Spence | Chief Commercial Officer |
| Mr. Rhys de Callier | Chief Strategy Officer |
| Ms. Cortney Caudill M.B.A. | Senior VP & COO |
| Ms. Tram Bui | Head of Investor Relations & Corporate Communications |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | halo-20260505.htm |
| 2026-04-30 | 8-K | halo-20260430.htm |
| 2026-04-24 | 8-K | halo-20260422.htm |
| 2026-03-23 | DEFA14A | proxyadditional2026.htm |
| 2026-03-23 | DEF 14A | halo-20260323.htm |
| 2026-03-12 | 8-K | halo-20260312.htm |
| 2026-02-17 | 10-K | halo-20251231.htm |
| 2026-01-28 | 8-K | halo-20260128.htm |
| 2025-12-09 | 8-K | halo-20251204.htm |
| 2025-12-08 | 8-K | halo-20251204.htm |